Why ImmunityBio, Inc.’s (IBRX) Stock Is Up 5.09%
As of Tuesday, November 03, ImmunityBio, Inc.’s IBRX share price has surged by 5.09%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Commentary & Analysis
Why ImmunityBio, Inc.’s (IBRX) Stock Is Down 5.59%
As of Friday, October 30, ImmunityBio, Inc.’s IBRX share price has dipped by 5.59%, which has investors questioning if this is right time to buy.Tudor Pop
Why ImmunityBio, Inc.’s (IBRX) Stock Is Up 5.76%
As of Tuesday, October 27, ImmunityBio, Inc.’s IBRX share price has surged by 5.76%, which has investors questioning if this is right time to sell.Jenna Brashear
Why ImmunityBio, Inc.’s (IBRX) Stock Is Down 8.22%
As of Monday, October 19, ImmunityBio, Inc.’s IBRX share price has dipped by 8.22%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why ImmunityBio, Inc.’s (IBRX) Stock Is Down 5.35%
As of Friday, October 16, ImmunityBio, Inc.’s IBRX share price has dipped by 5.35%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | IBRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8,478.7 | $214.3 | 76% |
|
| Shares Out (Mil) | 1,050.1 | 53.9 | 94% |
|
| Institutional Ownership | 41.8% | 92.9% | 18% |
|
| Float (Mil) | 406.7 | 41.4 | 83% |
|
| Beta | 0.13 | 0.96 | 10% |
|
| Avg Daily Volume (000s) | 8,830 | 506 | 95% |
|
| Price Change (52-week) |
284.6% | 43.9% | 99% |
|
| Growth | IBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 185.2% | 13.2% | 100% |
|
| Net Income (5yr) | (9.6%) | (10.1%) | 29% |
|
| EPS (5yr) | 8.3% | 15.8% | 44 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 11.4% | (15.7%) | 70% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 2 | 3 | |
| Current EPS | ($0.050) | ($0.915) | ($0.073) | |
| Month Ago EPS | ($0.050) | ($0.915) | ($0.140) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.050) | ($0.915) | ($0.127) | |
| Year/Year Chg | (77.2%) | 139.5% | (246.6%) | |
| Financials | IBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $166 | $37 | 30% |
|
| Net Income (TTM) (Mil) | ($992) | ($44) | 1% |
|
| EPS (TTM) | ($0.989) | ($1.500) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($281) | ($34) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($61) | $1 | 19% |
|
| Long-Term Debt (Q1) (Mil) | $1,221 | $4 | 68% |
|
| Enterprise Value (Q1) (Mil) | $9,859 | $172 | 73% |
|
| Valuation | IBRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.00 | na |
|
| P/E | na | 18.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | IBRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 99.3% | 67.3% | 96% |
|
| Net Margin | (598.6%) | (63.5%) | 1% |
|
| ROA | (192.6%) | (47.5%) | 2% |
|
| ROE | 122.7% | (53.3%) | 97% |
|
| Liabilities to Assets | 266.4% | 29.6% | 99% |
|
| F-Score | 3 | 2 | 18% |
|
ImmunityBio, Inc. did not pass any screens on 11/5/2026.
